Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAILORED-PROM
NCT07107477Phase 3Recruiting
- Sponsor
- Central and Eastern European Gynecologic Oncology Group
- Start
- May 2025
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Central and Eastern European Gynecologic Oncology Group. Primary endpoint: Latency of pregnancy of more than 7 days from premature rupture of membranes to delivery. Started May 2025; status: recruiting.
Beyond the preview
Go deeper on NCT07107477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07107477.